RETRACTED ARTICLE: The microRNA-325 inhibits hepatocellular carcinoma progression by targeting high mobility group box 1

Li, Huifen; Huang, Weihua; Luo, Rong

doi:10.1186/s13000-015-0323-z

Cited by 27 publications

(12 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miR-325 has the potential of a tumor suppressor which is reflected by the promotion of tumor progression, increased angiogenesis, invasion and metastasis. 30 There is a lack of specific data regarding miR-325 expression in the context of ovarian cancer or endometriosis, but there are several studies reporting its role in other malignant pathologies. 31 , 32 This way, the degree of expression of miR-325 can be utilized as a clinical parameter for detecting ovarian cancer invasion, 31 whose expression is inhibited in these tumors.…”

Section: Discussionmentioning

confidence: 99%

miRNA expression profiling in formalin-fixed paraffin-embedded endometriosis and ovarian cancer samples

Braicu¹,

Budişan²,

Buiga³

et al. 2017

OTT

View full text Add to dashboard Cite

Endometriosis is an inflammatory pathology associated with a negative effect on life quality. Recently, this pathology was connected to ovarian cancer, in particular with endometrioid ovarian cancer. microRNAs (miRNAs) are a class of RNA transcripts ~19–22 nucleotides in length, the altered miRNA pattern being connected to pathological status. miRNAs are highly stable transcripts, and these can be assessed from formalin-fixed paraffin-embedded (FFPE) samples leading to the identification of miRNAs that could be developed as diagnostic and prognostic biomarkers, in particular those involved in malignant transformation. The aim of our study was to evaluate miRNA expression pattern in FFPE samples from endometriosis and ovarian cancer patients using PCR-array technology and also to compare the differential expression pattern in ovarian cancer versus endometriosis. For the PCR-array study, we have used nine macrodissected FFPE samples from endometriosis tissue, eight samples of ovarian cancers and five normal ovarian tissues. Quantitative real-time PCR (qRT-PCR) was used for data validation in a new patient cohort of 17 normal samples, 33 endometriosis samples and 28 ovarian cancer macrodissected FFPE samples. Considering 1.5-fold expression difference as a cut-off level and a P-value <0.05, we have identified four miRNAs being overexpressed in endometrial tissue, while in ovarian cancer 15 were differentially expressed (nine overexpressed and six downregulated). The expression level was confirmed by qRT-PCR for miR-93, miR-141, miR-155, miR-429, miR-200c, miR-205 and miR-492. Using the interpretative program Ingenuity Pathway Analysis revealed several deregulated pathways due to abnormal miRNA expression in endometriosis and ovarian cancer, which in turn is responsible for pathogenesis; this differential expression of miRNAs can be exploited as a therapeutic target. A higher number of altered miRNAs were detected in endometriosis versus ovarian cancer tissue, most of them being linked with epithelial-to-mesenchymal transition.

show abstract

Section: Discussionmentioning

confidence: 99%

miRNA expression profiling in formalin-fixed paraffin-embedded endometriosis and ovarian cancer samples

Braicu¹,

Budişan²,

Buiga³

et al. 2017

OTT

View full text Add to dashboard Cite

show abstract

“…The editor has retracted this article [ 1 ] because it shows significant overlap with the following articles (amongst others) [ 2 , 3 ]. None of the authors responded to correspondence regarding this retraction.…”

Section: Retractionmentioning

confidence: 99%

Retraction Note: The microRNA-325 inhibits hepatocellular carcinoma progression by targeting high mobility group box 1

Li¹,

Huang²,

Luo³

2018

Diagn Pathol

Self Cite

View full text Add to dashboard Cite

“…30 miR-325 can inhibit hepatocellular carcinoma progression by targeting HMGB1. 31 miR-218 can suppress the progression of pancreatic cancer cells by inhibiting HMGB1. 32 Serum HMGB1 is closely correlated with the clinical and pathogenesis of GC.…”

Section: Discussionmentioning

confidence: 99%

miR‐505 acts as a tumor suppressor in gastric cancer progression through targeting HMGB1

Tian

Wang

Hao

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Gastric cancer (GC) is a frequent type of malignant tumor worldwide. GC metastasis results in the majority of clinical treatment failures. MicroRNAs (miRNA) are identified to exhibit crucial roles in GC. Our current study aimed to explore the biological roles of miR‐505 in GC progression. It was observed that miR‐505 was robustly decreased in GC cells compared with human normal gastric epithelial GES‐1 cells. Overexpression of miR‐505 was able to repress GC progression in AGS and BGC‐823 cells. In addition, high‐mobility group box 1 (HMGB1) has been identified as a crucial oncogene in several cancer types. By carrying out bioinformatics analysis, HMGB1 was predicted as a direct target of miR‐505. Meanwhile, HMGB1 was found to be significantly increased in GC cells and it was confirmed in our study that miR‐505 can directly target HMGB1 in vitro. miR‐505 mimics can inhibit HMGB1 messenger RNA and protein expression dramatically. Subsequently, knockdown of HMGB1 can inhibit GC cell proliferation, colony formation, and induce cell apoptosis. Furthermore, HMGB1 silence suppressed GC cell migration and invasion greatly in vitro. Finally, it was validated that miR‐505 can inhibit GC progression by targeting HMGB1 in vivo. Taken these together, it was indicated that miR‐505/HMGB1 axis was involved in the development of GC. miR‐505 can serve as a potential prognostic indicator in GC therapy.

show abstract

RETRACTED ARTICLE: The microRNA-325 inhibits hepatocellular carcinoma progression by targeting high mobility group box 1

Cited by 27 publications

References 37 publications

miRNA expression profiling in formalin-fixed paraffin-embedded endometriosis and ovarian cancer samples

miRNA expression profiling in formalin-fixed paraffin-embedded endometriosis and ovarian cancer samples

Retraction Note: The microRNA-325 inhibits hepatocellular carcinoma progression by targeting high mobility group box 1

miR‐505 acts as a tumor suppressor in gastric cancer progression through targeting HMGB1

Contact Info

Product

Resources

About